Proactive - Interviews for investors

Immunic Inc chief scientific officer Hella Kohlhof talked with Proactive's Stephen Gunnion about the significance of Crohn's and Colitis Awareness Week. She outlined the challenges of inflammatory bowel disease (IBD), a chronic and serious condition affecting the digestive tract. "It's not just a regular stomach issue; it's a lifelong disease," she explained, emphasizing the debilitating symptoms such as abdominal pain, fatigue, and weight loss.

Kohlhof discussed Immunic's innovative research projects targeting IBD. The company's IMU-856 aims to restore the gut lining's functionality through epigenetic modulation, while IMU-381 focuses on anti-inflammatory properties, addressing different aspects of gastrointestinal health.

She encouraged viewers to explore resources provided by advocacy groups like the Crohn's and Colitis Foundation and to talk openly about IBD, helping to reduce the stigma and promote awareness. "Please speak about the disease and inform others to see a doctor if they have symptoms," Kohlhof urged.

Stay tuned to Proactive's YouTube channel for more interviews with key figures in science and business. Don’t forget to like this video, subscribe to our channel, and turn on notifications for the latest updates.

#ibdawareness #CrohnsDisease #UlcerativeColitis #InflammatoryBowelDisease #GutHealth #ImmunicInc #MedicalResearch #HealthAwareness #Epigenetics #ProactiveInterviews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Firebird Metals Ltd (ASX:FRB, OTC:FRBMF) managing director Peter Allen talks with Proactive’s Tylah Tully about the company’s LMFP strategy and its achievements in 2024.

Allen shared insights on the growing importance of lithium manganese iron phosphate (LMFP) batteries, explaining how this technology improves energy density and range while maintaining safety and cost benefits.

He highlighted the company’s advancements, including establishing a subsidiary in China, completing feasibility studies and building a pilot plant for its innovative processing kiln.

Firebird Metals also secured essential permits and collaborated with Central Southern University on developing cathode materials.

Looking ahead, Allen discussed goals to commercialise the kiln for broader applications, finalise royalty agreements with traditional owners and enhance supply reliability through upcoming agreements.

He emphasised the company’s focus on innovation and readiness to meet the rising demand for LMFP technology in the next 18–24 months.

#ProactiveInvestors #FirebirdMetals #ASX #LMFPStrategy #BatteryTechnology #LithiumManganese #EnergyDensity #Innovation #ASXStocks #ChinaMarket #SustainableEnergy #2024Milestones

Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Great Boulder Resources Ltd (ASX:GBR).

The company has received high-grade gold intersections from resource definition drilling at the Saltbush prospect within its Side Well Gold Project in Western Australia, which holds a mineral resource estimate of 668,000 ounces at 2.8 g/t gold.

Recent drilling at Saltbush returned notable results, including 8 metres at 7.59 g/t from 12 metres with 5 metres at 10.14 g/t within that intersection. The drilling also confirmed that the mineralisation extends to the north and remains open in this direction, suggesting significant potential for an extension to the strike length of the deposit. Managing director Andrew Paterson expressed satisfaction with the results, emphasising the prospect's potential for further development.

At the Side Well South prospect, initial aircore drilling identified gold mineralisation along strike from historical workings at the Golden Bracelet mine. Aircore drilling has resumed in the area and further results are expected.

Great Boulder is advancing other initiatives, including RC drilling at Mulga Bill North and Mulga Bill, aircore drilling at Side Well South and auger sampling over the Wanbanna joint venture tenements. Metallurgical testing on samples from Mulga Bill is ongoing, with results anticipated early next year. The company has deferred a planned resource update to incorporate results from these additional drilling campaigns.

#ProactiveInvestors #GreatBoulderResources #ASX #JusttheFacts #GoldExploration #SaltbushProspect #SideWellGoldProject #HighGradeGold #WesternAustralia #GoldDrilling #MineralResource #MiningNews #GoldMining #ExplorationUpdates #RCDrilling #AircoreDrilling #GoldDiscovery #GoldenBraceletMine #AustralianMining #Mineralisation #MiningInvestment #MetallurgicalTesting #ResourceUpdate

Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Orthocell Ltd (ASX:OCC, OTC:ORHHF).

The company has completed a pivotal US FDA 510(k) regulatory study for its nerve repair device, Remplir™, demonstrating its safety and efficacy in peripheral nerve surgery. This marks a critical step towards gaining US market clearance. The study met all required endpoints using a rat sciatic nerve model, showing that Remplir effectively regenerates nerves with outcomes comparable to an FDA-approved control.

Key findings included restored motor and sensory functions, absence of adverse tissue reactions and high-quality nerve regeneration within 12 weeks post-treatment. Orthocell highlighted the results as a validation of Remplir’s superior clinical outcomes, previously published in a peer-reviewed journal.

The company remains on schedule to submit its 510(k) application this month with FDA clearance anticipated in the first quarter of 2025. Upon approval, Orthocell aims to enter the US$1.6 billion nerve repair market. Remplir is already approved in Australia, New Zealand and Singapore, with increasing adoption by surgeons.

Orthocell has cash reserves of approximately A$33 million, which support its planned US commercial launch and further global expansion. The company has also appointed US sales and medical affairs teams to prepare for market entry and is poised to establish distribution partnerships following FDA clearance.

#ProactiveInvestors #Orthocell #ASX #JusttheFacts #Remplir #FDAApproval #NerveRepair #MedicalDevice #ClinicalStudy #HealthcareTechnology #PeripheralNerveSurgery #MedicalInnovation #BiotechNews #USMarketLaunch #FDA510k #RegenerativeMedicine #SurgicalSolutions #Orthopaedics #MarketExpansion #HealthTech #GlobalGrowth #MedicalBreakthroughs

Arrow Exploration CEO Marshall Abbott joined Steve Darling from Proactive to share a record-breaking Q3 performance and detailed plans for continued growth in 2025. The company achieved its strongest quarter ever in production, revenue, EBITDA, and cash flow. The company saw total revenue of $21.3 million, a 53% increase from Q3 2023. Net income of $6.7 million and adjusted EBITDA of $15.9 million, up 62% from Q3 2023 and 79% from Q2 2024. Operating cash flow of $29.2 million for the nine months ending September 30, 2024 and a cash position of $16.5 million at the end of the quarter.

Operationally, abbott told Proactive the company successfully drilled three horizontal development wells at the Carrizales Norte (CN) field, contributing significantly to these results. The company plans further activity at the Alberta Llanos prospect, starting with a low-risk vertical exploration well targeting multiple formations. Two additional vertical wells are also planned on the same pad.

Looking ahead to 2025, Arrow has ambitious plans to drill up to 23 wells using two rigs. Rig 1 will be focused on Alberta Llanos, Carrizales Norte, Mateguafa Oeste, and Capullo prospects. Rig 2 will be dedicated to the RCE development area and a new Carrizales Norte C pad for horizontal drilling in the northern section of the field. The company is also planning a 3D seismic project over the Tapir block’s southern area will target further development of the Icaco and Macoya prospects.

The company has allocated $50 million in capital expenditures for 2025, with production expected to rise significantly as a result. This comprehensive growth strategy positions Arrow Exploration for a strong year ahead.

#proactiveinvestors #arrowexplorationinc #aim #axl #tsxv #axl

#OilAndGas #EnergySector #FinancialResults #UbaqueReservoir #TapirBlock #CapEx2025 #OilExploration #SeismicSurvey #EnergyInvesting#invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Proactive’s Billy Farrington joined Stephen Gunnion for the weekly Crypto Roundup, offering insights into the latest market developments. Bitcoin began the week with a sharp dip, dropping 5% on Monday. However, a midweek rebound saw Bitcoin stabilise at $97,200—just shy of its recent all-time high. Farrington explained, “The Trump trade sugar rush has tapered off,” highlighting that ETF inflows have slowed and retail investor interest appears to have cooled.

Looking ahead, Farrington noted that while Bitcoin’s historical performance in December has been strong, reaching the $100,000 milestone may face challenges due to profit-taking and market resistance.

Ripple has been another standout performer, tripling its value in just a month. Farrington attributed this surge to regulatory developments, including SEC Chairman Gary Gensler’s resignation, which signals a potentially friendlier regulatory environment for crypto under the incoming administration.

Ripple’s market capitalisation now stands at $96 billion, making it the fifth-largest cryptocurrency.

Stay tuned for more in-depth updates and analysis in our weekly Crypto Roundup. Don’t forget to like, subscribe, and enable notifications to stay informed on all things crypto.

#CryptoRoundup #Bitcoin #Ripple #CryptoNews #BTCPrice #RippleSurge #BitcoinAnalysis #CryptoInvesting #Blockchain #DigitalAssets #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Faron Pharmaceuticals Limited (AIM:FARN) chief medical officer Dr Petri Bono speaks with Proactive's Stephen Gunnion about the promising interim results from the phase II BEXMAB trial. This trial targets relapsed and refractory myelodysplastic syndrome (MDS) with their anti-Clever-1 antibody, bexmarilimab.

Bono highlighted that BEXMAB treatment combined with azacitidine showed a median survival of 13.5 months, significantly surpassing the historical survival rate of 5 to 6 months. He noted an exceptional 80% overall response rate in patients who had no other treatment options. These results represent significant progress for this challenging patient population.

Additionally, he shared that detailed clinical, translational, and safety findings would be presented at the American Society of Hematology annual meeting in December 2024. He confirmed that the full phase II results are expected by the end of Q1 2025, with enrollment ongoing in the US, Finland, and soon the UK.

Visit Proactive’s YouTube channel for more interviews and updates. Don’t forget to like, subscribe, and hit the notification bell to stay informed.

#FaronPharmaceuticals #BEXMAB #MDSResearch #ClinicalTrials #Hematology #CancerResearch #Bexmarilimab #MedicalBreakthroughs #PharmaNews #ProactiveUpdates #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Proactive’s Tylah Tully gives another ‘Small Caps Wrap,’ outlining the biggest movers across the ASX small caps sector.

Orthocell Ltd was among the strongest performers, rising nearly 34% to a weekly high of $0.83 before entering a trading halt at $0.81.

The company’s share price surged after it announced a distribution agreement with Device Technologies Asia to exclusively market and distribute its nerve repair product Remplir™ in Singapore.

This marks the product’s first significant international expansion beyond Australia and New Zealand, supported by recent regulatory approval from Singapore’s Health Sciences Authority.

At its AGM, Orthocell Chair Paul Anderson highlighted a 30% revenue growth over the past financial year, with a promising trajectory for continued growth.

European Lithium Ltd increased by 46%, trading at $0.037 by the end of the week.

The company announced the acquisition of the Leinster Lithium Project in Ireland. This project is noted for its consistent high-grade lithium oxide at surface, with grades ranging between 2.5% and 3.5% lithium.

QMines Ltd rose by 23% on Thursday, reaching a weekly high of $0.073 and closing at $0.064.

The increase followed results from its maiden drilling program at the Develin Creek Project.

Key intersections included 26 metres at 1.38% copper, 0.29 g/t gold, 11g/t silver and 1.99% zinc.

Other notable risers included Move Logistics Group Ltd, which added $0.035 to its share price, ending at $0.175.

Errawarra Resources Ltd saw a 50% increase, trading at $0.09 after announcing a joint venture with Falcon Metals.

Element 25 Ltd jumped by 21.6% to a high of $0.31, Nova Minerals Ltd rose by 19.1% to reach $0.25 and Anteris Technologies Ltd was 78 cents, or 8.56%, higher to $9.90.

#ProactiveInvestors #ASX #SmallCaps #SmallCapWrap #Orthocell, #EuropeanLithium, #QMines, #StockMarket, #LithiumMining, #CopperExploration, #Remplir, #SingaporeExpansion, #DeviceTechnologies, #ASX, #StockMarketNews, #MiningProjects, #Investing, #FalconMetals, #Errawarra, #DevelinCreek, #NerveRepair, #LithiumStocks, #GrowthStocks

Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Tryptamine Therapeutics Limited (ASX: TYP).

Tryp has concluded its Phase 1b study of TRP-8803, an IV-infused psilocin-based formulation, in obese participants.

Conducted at CMAX Clinical Research in Adelaide, the trial safely administered the treatment to three participants over a 140-minute period, completing the study within a week.

This rapid timeframe highlights the formulation’s scalability and potential.

TRP-8803 is designed to provide neuroplastic benefits, with applications for adaptive brain changes linked to psychiatric improvements.

The study generated valuable human data to optimise dosing for upcoming Phase 2 trials, targeting weight-related conditions such as Binge Eating Disorder.

Results, expected by the year’s end, will guide the advanced planning of the Phase 2 program. Tryptamine noted that all participants were safely discharged post-administration, marking a significant milestone in demonstrating the formulation’s potential to deliver improved health outcomes efficiently.

The company emphasises TRP-8803’s broad research opportunities and looks forward to leveraging the final dataset to explore its efficacy in addressing unmet medical needs within large market opportunities.

#ProactiveInvestors #TrypTherapeutics #ASX #JusttheFacts #TRP8803, #ClinicalTrials, #PsilocinResearch, #Neuroplasticity, #BingeEatingDisorder, #IVTherapy, #ObesityResearch, #DrugDevelopment, #MentalHealthTreatment, #PsilocybinTherapy, #HealthInnovation, #CMAXResearch, #PharmaceuticalInnovation, #ClinicalStudy, #WeightManagement, #Biopharma, #Phase2Trials, #MedicalBreakthroughs, #TherapeuticResearch

Proactive’s Tylah Tully breaks down ‘Just the Facts’ of the latest news from Titan Minerals Ltd (ASX:TTM, OTC:TTTNF).

The company has announced significant high-grade gold discoveries from trenching activities at the Dynasty Gold Project in Ecuador.

At the Cerro Verde east and south prospect, trenching returned 2.1 metres at 32 g/t gold and 7.4 g/t silver, and another trench returned 2 metres at 7.3g/t gold and 6.1g/t silver.

The trenching program has validated the potential of multiple targets identified through high-grade rock chips, mapped veins and soil geochemical anomalies.

Titan says these results provide “proof of concept” for new target areas set for further testing under a 10,000-metre exploration and resource growth drilling program.

The company emphasises that gold mineralisation at Dynasty outcrops at surface, making trenching an effective and economical method to evaluate mineralisation.

Currently, three diamond drill rigs are operational, with completed samples sent for laboratory analysis.

Drill results are anticipated in the coming weeks and will contribute to a resource update planned for mid-2025.

#ProactiveInvestors #TitanMinerals #ASX #JusttheFacts #GoldExploration, #DynastyProject, #MiningEcuador, #HighGradeGold, #GoldMining, #ResourceUpdate, #Mineralisation, #TrenchingResults, #CerroVerde, #GeochemicalAnomalies, #DiamondDrilling, #PreciousMetals, #GoldProspecting, #MiningNews, #GoldDiscovery, #EcuadorMining, #SurfaceTrenching, #GoldSilver, #ExplorationDrilling